The Future of Medicine: an Outline Attempt Using State-of-the-art Business and Scientific Trends

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Aug 22

PMID 39170042

Authors

Gregorios Agyralides

Affiliations

Soon will be listed here.

Abstract

Introduction: Currently, there is a lot of discussion about the future of medicine. From research and development to regulatory approval and access to patients until the withdrawal of a medicinal product from the market, there have been many challenges and a lot of barriers to overcome. In parallel, the business environment changes rapidly. So, the big question is how the pharma ecosystem will evolve in the future.

Methods: The current literature about the latest business and scientific evolutions and trends was reviewed.

Results: In the business environment, vast changes have taken place via the development of the internet as well as the Internet of Things. A new approach to production has emerged in a frame called Creative Commons; producer and consumer may be gradually identified in the context of the same process. As technology rapidly evolves, it is dominated by Artificial Intelligence (AI), its subset, Machine Learning, and the use of Big Data and Real-World Data (RWD) to produce Real-World Evidence (RWE). Nanotechnology is an inter-science field that gives new opportunities for the manufacturing of devices and products that have dimensions of a billionth of a meter. Artificial Neural Networks and Deep Learning (DL) are mimicking the use of the human brain, combining computer science with new theoretical foundations for complex systems. The implementation of these evolutions has already been initiated in the medicinal products' lifecycle, including screening of drug candidates, clinical trials, pharmacovigilance (PV), marketing authorization, manufacturing, and the supply chain. This has emerged as a new ecosystem which features characteristics such as free online tools and free data available online. Personalized medicine is a breakthrough field where tailor-made therapeutic solutions can be provided customized to the genome of each patient.

Conclusion: Various interactions take place as the pharma ecosystem and technology rapidly evolve. This can lead to better, safer, and more effective treatments that are developed faster and with a more solid, data-driven and evidence-concrete approach, which will drive the benefit for the patient.

References

Rodier C, Bujar M, McAuslane N, Patel P, Liberti L . Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice. Ther Innov Regul Sci. 2020; 55(1):118-128. PMC: 7785566. DOI: 10.1007/s43441-020-00196-2. View

. International Conference on Harmonisation; guidance on electronic common technical document specification; availability. Notice. Fed Regist. 2003; 68(63):16060-1. View

Tran T, Tayara H, Chong K . Recent Studies of Artificial Intelligence on Drug Absorption. J Chem Inf Model. 2023; 63(20):6198-6211. DOI: 10.1021/acs.jcim.3c00960. View

Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade R . Artificial intelligence in drug discovery and development. Drug Discov Today. 2020; 26(1):80-93. PMC: 7577280. DOI: 10.1016/j.drudis.2020.10.010. View

Delpierre C, Lefevre T . Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Front Sociol. 2023; 8:1112159. PMC: 9989160. DOI: 10.3389/fsoc.2023.1112159. View

Alvaro N, Conway M, Doan S, Lofi C, Overington J, Collier N . Crowdsourcing Twitter annotations to identify first-hand experiences of prescription drug use. J Biomed Inform. 2015; 58:280-287. DOI: 10.1016/j.jbi.2015.11.004. View

Schad F, Thronicke A . Real-World Evidence-Current Developments and Perspectives. Int J Environ Res Public Health. 2022; 19(16). PMC: 9408280. DOI: 10.3390/ijerph191610159. View

Harrer S, Shah P, Antony B, Hu J . Artificial Intelligence for Clinical Trial Design. Trends Pharmacol Sci. 2019; 40(8):577-591. DOI: 10.1016/j.tips.2019.05.005. View

Morley J, DeVito N, Zhang J . Generative AI for medical research. BMJ. 2023; 382:1551. DOI: 10.1136/bmj.p1551. View

10.

Ahmed Z, Mohamed K, Zeeshan S, Dong X . Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database (Oxford). 2020; 2020. PMC: 7078068. DOI: 10.1093/database/baaa010. View

11.

Bean D, Wu H, Iqbal E, Dzahini O, Ibrahim Z, Broadbent M . Knowledge graph prediction of unknown adverse drug reactions and validation in electronic health records. Sci Rep. 2017; 7(1):16416. PMC: 5703951. DOI: 10.1038/s41598-017-16674-x. View

12.

Gams M, Horvat M, Ozek M, Lustrek M, Gradisek A . Integrating artificial and human intelligence into tablet production process. AAPS PharmSciTech. 2014; 15(6):1447-53. PMC: 4245424. DOI: 10.1208/s12249-014-0174-z. View

13.

Liu B, He H, Luo H, Zhang T, Jiang J . Artificial intelligence and big data facilitated targeted drug discovery. Stroke Vasc Neurol. 2020; 4(4):206-213. PMC: 6979871. DOI: 10.1136/svn-2019-000290. View

14.

Sanchez-Pinto L, Luo Y, Churpek M . Big Data and Data Science in Critical Care. Chest. 2018; 154(5):1239-1248. PMC: 6224705. DOI: 10.1016/j.chest.2018.04.037. View

15.

Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S . The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature. Pharmaceut Med. 2022; 36(5):295-306. DOI: 10.1007/s40290-022-00441-z. View

16.

Dewulf P, Stock M, De Baets B . Cold-Start Problems in Data-Driven Prediction of Drug-Drug Interaction Effects. Pharmaceuticals (Basel). 2021; 14(5). PMC: 8147651. DOI: 10.3390/ph14050429. View

17.

Simoes M, Silva G, C Pinto A, Fonseca M, Silva N, Pinto R . Artificial neural networks applied to quality-by-design: From formulation development to clinical outcome. Eur J Pharm Biopharm. 2020; 152:282-295. DOI: 10.1016/j.ejpb.2020.05.012. View

18.

Basile A, Yahi A, Tatonetti N . Artificial Intelligence for Drug Toxicity and Safety. Trends Pharmacol Sci. 2019; 40(9):624-635. PMC: 6710127. DOI: 10.1016/j.tips.2019.07.005. View

19.

Williamson B . Gene therapy. Gut. 1992; 33(12):1585-6. PMC: 1379564. DOI: 10.1136/gut.33.12.1585. View

20.

Sudhakar V, Richardson R . Gene Therapy for Neurodegenerative Diseases. Neurotherapeutics. 2018; 16(1):166-175. PMC: 6361055. DOI: 10.1007/s13311-018-00694-0. View